CD8A and cancer: The existence of cancer-specific stem-like CD8+ T cells in the secondary lymphoid organs noted in this study is relevant to these previous reports, and in terms of long-term survival of functional cancer antigen-specific T cells in the spleen and bone marrow, which proliferated upon encountering cancer antigen-loaded splenic DCs 2 months after cancer treatment (Figure 6), indicating that mJX-594 treatment elicits long-term anticancer immune responses.